Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 12,225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions: Rencofilstat, Placebo; Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more

Conditions: Ehlers-Danlos Syndrome, Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Genetic Disease Investigators; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Colleyville, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Placebo, PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C, PF-06342674 Dose D; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Thrombotic Thrombocytopenic Purpura
Interventions: Cyclosporine, Prednisone; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Female Sexual Dysfunction, Multiple Sclerosis, Spinal Cord Injury
Interventions: Sympathetic manipulation on sexual arousal in women; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions: Treatment with HydroPearl via radial access; Device
Lead sponsor: Terumo Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more

Conditions: Prostate Cancer
Interventions: Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg, Leuprolide 7.5 mg / Degarelix 160 mg; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Homewood, Alabama • Laguna Hills, California • Torrance, California + 11 more

Conditions: Chronic Inducible Urticaria
Interventions: Remibrutinib, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions: Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 50 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hemophilia A
Interventions: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)); Biological
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions: RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 60 Years and older
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions: Iloprost, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Major Depressive Disorder
Interventions: AGO178; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 95
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 81 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Placebo, Ocrelizumab, Avonex; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 26
States / cities: Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more

Conditions: Acute-On-Chronic Liver Failure, Ascites
Interventions: VS-01 on top of SOC, SOC (Control Group); Drug · Other
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Infertility
Interventions: Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Pasadena, California • San Diego, California • Littleton, Colorado + 4 more

Conditions: Smith-Lemli-Opitz Syndrome
Interventions: Simvastatin Susp., OraPlus; Drug
Lead sponsor: Forbes Porter, M.D.; NIH
Eligibility: 4 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acne Vulgaris
Interventions: ASC-J9 cream, placebo; Drug
Lead sponsor: AndroScience Corp; Industry
Eligibility: 12 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Fremont, California • San Diego, California • Boise, Idaho + 7 more

Conditions: Chronic Pain, Marfan Syndrome, Vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome
Interventions: Empowered Relief; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Diabetes Mellitus, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Facet Joint Pain
Interventions: Glyder; Device
Lead sponsor: Zyga Technology, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Santa Monica, California • Tampa, Florida • Edmond, Oklahoma + 1 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Effects of Spinal Cord Injury on Female Sexual Response

An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Preservation of Ovarian Function After Hematopoietic Cell Transplant

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

MENOPUR® Versus FOLLISTIM®

Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions

Allergic Disease Onset Prevention Study

Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus

A Multi-Site Study of the Zyga GlyDer Facet Restoration Device In Subjects With LUmbar FacET Pain Syndrome - DUET